BridgeBio Pharma Inc at Bank of America Global Healthcare Conference Transcript
Thanks so much. Really appreciate the time and the opportunity to present here, and thanks for everyone for coming.
There's a lot going on right now at BridgeBio. We have 3 Phase IIIs already commenced or about to commence in ADH1, achondroplasia, and LGMD2i, and obviously, an important Phase II data set reading out later this year in congenital adrenal hyperplasia. But I wanted to spend the entirety of my time today talking about a key program in ATTR-Cardiomyopathy, one of our big catalysts that's upcoming this year, which is the final readout from our Phase III ATTRibute trial.
And I want to spend some time on -- move this forward to Slide 2. The key questions highlighted on this second slide. First of all, what are the clinical expectations from this trial? And how might we compare the clinical data that we produce from a tribute to already available therapies and specifically, what does superiority look like?
I want to then tie those clinical expectations to commercial expectations, where we've
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
